

Global Blood Cancer Drugs Market Is Expected To Grow At A CAGR of 7.3% During 2018-2022

TheBusinessResearchCompany.com offers Blood Cancer Drugs Global Market Report 2019 from its research database.



The global blood cancer drugs market was valued at about \$33 billion in 2018 and is expected to grow to \$43.74 billion at a CAGR of 7.3% through 2022."

Abdul Wasay

LONDON, GREATER LONDON, UK, December 31, 2019 /EINPresswire.com/ -- Take a look at our year-end deals on Opportunities and Strategies Reports! Up to 50% off on all licenses.

<https://www.thebusinessresearchcompany.com/discounted-reports.aspx>

The global blood cancer drugs market was valued at about \$33 billion in 2018 and is expected to grow to \$43.74 billion at a CAGR of 7.3% through 2022. The blood cancer drugs market is being driven by the growing death incidences

and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death.

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukemia, lymphoma, and myeloma. The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others

Request For A Free Sample For The Global Blood Cancer Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp>

The global blood cancer drugs market is further segmented based on type and geography. By Type - The blood cancer drugs market is segmented into leukemia, lymphoma, myeloma. By Geography - The global blood cancer drugs is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Amongst these, North America was the largest region in the blood cancer drugs market in 2018, followed by Europe. This region is expected to remain the largest during the next five years. The blood cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Read More On The Report For The Global Blood Cancer Drugs Market At:

<https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report>

Trends In The Blood Cancer Drugs Market

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large

sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

Major players in the Blood Cancer Drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly.

Blood Cancer Drugs Global Market Report 2019 is one of a series of new reports from The Business Research Company that provides blood cancer drugs market overviews, analyzes and forecasts blood cancer drugs market size and growth for the global blood cancer drugs market, blood cancer drugs market share, blood cancer drugs market players, blood cancer drugs market size, blood cancer drugs market segments and geographies, blood cancer drugs market trends, blood cancer drugs market drivers and blood cancer drugs market restraints, blood cancer drugs market's leading competitors' revenues, profiles and market shares. The blood cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors' approaches.

Where To Learn More

Read Blood Cancer Drugs Global Market Report 2019 from The Business Research Company for information on the following:

Markets Covered: global blood cancer drugs market

Data Segmentations: Blood cancer drugs market size, global and by country; historic and forecast size, and growth rates for the world, 7 regions and 12 countries

Blood Cancer Drugs Market Organizations Covered: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Time Series: Five years historic (2014-18) and forecast (2018-22).

Other Information And Analyses: PESTEL analysis, blood cancer drugs market customer information, blood cancer drugs market product/service analysis – product examples, blood cancer drugs market trends and opportunities, drivers and restraints, key mergers and acquisitions, key metrics covered: number of enterprises, number of employees, global blood cancer drugs market in 2019 - countries offering most new opportunities

Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes.

Strategies For Participants In The Blood Cancer Drugs Industry: the report explains a number of strategies for companies in the blood cancer drugs market, based on industry trends and company analysis.

Opportunities For Companies In The Blood Cancer Drugs Sector: The report reveals where the global blood cancer drugs industry will put on most \$ sales up to 2022.

Interested to know more about The Business Research Company?

The Business Research Company has published over 300 industry reports, covering over 2400 market segments and 56 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. Here is a list of reports from The Business Research Company similar to Blood Cancer Drugs Global Market Report 2019:

[Pharmaceutical Drugs Market](#) By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-infective Drugs, Metabolic Disorder Drugs, Central Nervous System

Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology
Drugs, Dermatology Drugs, Ophthalmology Drugs) - Global Forecast To 2022
[Biologics Market](#) By Types (Monoclonal Antibodies, Therapeutic Proteins And Vaccines), By
Trends, By Regions And By Key Players - Global Forecast To 2021
[Stem Cell/Cord Blood Banking Global Market Report 2019](#)

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email us here](#)
Visit us on social media:
[Facebook](#)
[Twitter](#)
[LinkedIn](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.